Real-world analysis of eptinezumab in chronic migraine shows increased dosing frequency or amount improved outcomes in patients with insufficient initial response.
Key findingReal-world analysis of eptinezumab in chronic migraine shows increased dosing frequency or amount im
What the researchers found
Real-world analysis of eptinezumab in chronic migraine shows increased dosing frequency or amount improved outcomes in patients with insufficient initial response.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Three subgroups analyzed: psychiatric comorbidities, prior subcutaneous anti-CGRP treatment, and migraine-associated brain fog. Outcome: increase in good days.
How the study worked
In publication.
Who was studied
Adults with chronic migraine including subgroups with psychiatric conditions, brain fog, or prior anti-CGRP treatment
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Real-world effectiveness of eptinezumab in chronic migraine-increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog.
The journal of headache and pain, 26(1), 274
Citation
Argoff, Charles; Khan, Fawad A; Herzog, Steven P; Smith, Ryan M; Soni-Brahmbhatt, Seema; Asher, Divya; Awad, Susanne F; Grossman, S Wald; Patel, Foram; Buse, Dawn C. (2025). Real-world effectiveness of eptinezumab in chronic migraine-increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog.. The journal of headache and pain, 26(1), 274. https://doi.org/10.1186/s10194-025-02165-2